GSK to pay $300M to license drug it sees as potential lupus treatment

The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax

Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy

March 10, 2026

Cobalt mine in DRC poisoning communities, displacing thousands – Report – EnviroNews

March 10, 2026

Source link

GSK to pay $300M to license drug it sees as potential lupus treatment

Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy

Cobalt mine in DRC poisoning communities, displacing thousands – Report – EnviroNews

Artists Kim Schoen and Kim Schoenstadt make light of mistaken identities in collaborative show

UK Royal Navy to Renovate Merlin Helicopter Fleet Base in Cornwall

UK Royal Navy to Renovate Merlin Helicopter Fleet Base in Cornwall

Leave a Reply Cancel reply

RECOMMENDED NEWS

USD Collapse, Jack Mallers & Elon Musk Warn of U.S. Bankruptcy!

Is Ether the Same as Ethereum?

At Harvard, a Battle Over What Should Be Said About the Hamas Attacks

10 U.S. Sectors To Be Affected If BRICS Stops Using the Dollar

POPULAR NEWS

Mahama attends Liberia’s 178th independence anniversary

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

GSK to pay $300M to license drug it sees as potential lupus treatment

Related posts

Artists Kim Schoen and Kim Schoenstadt make light of mistaken identities in collaborative show

UK Royal Navy to Renovate Merlin Helicopter Fleet Base in Cornwall

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS